Effect of obesity on biodistribution of nanoparticles

Abstract

Nanoparticles have specific features (lipophilicity, surface charge, composition and size). Studies regarding the biological behavior of nanoparticles in diseases such diabetics and obesity are scarce. Here, we evaluated two nanoparticles: magnetic core mesoporous silica (MSN) (58 nm) and polycaprolactone (PCL) nanoparticle (280 nm) in obese mice. Changes in the biodistribution were observed, especially considering the mononuclear phagocyte system (MPS), and the visceral fat tissue. Nonetheless, our data corroborates the influence of size in the biodistribution in obese animals, supporting that smaller nanoparticles, may show a higher tissue deposition at spleen, due the associated splenomegaly and the complications arising from this state. Finally, our study demonstrated that, in obesity, probably due the low-grade inflammatory state associated with metabolic syndrome a difference in accumulation of nanoparticles was found, with profound impact in the tissue deposition of nanoparticles.

Molecular and Cellular Risk Assessment of Healthy Human Cells and Cancer Human Cells Exposed to Nanoparticles

“…In order to evaluate the cell viability we performed the MTT assay testing a dose of 20 ug/mL. This dose has been used by our group in a variety of studies in vitro (22,(45)(46). However, there is a lack of evidence related to the toxic effects of this dose.…”

In loco retention effect of magnetic core mesoporous silica nanoparticles doped with trastuzumab as intralesional nanodrug for breast cancer

“…The confection and characterization of the magnetic core mesoporous silica nanoparticles has been previously described in detail by Pinto et al [5], Portilho et al [6] and de Jesus Felismino et al [7]. Briefly, the magnetic core mesoporous silica nanoparticles were prepared by sol-gel reaction, followed by insertion of Fe 3 O 4 magnetite nanocrystals produced by the coprecipitation methodology, into a modified synthesis methodology of mesoporous silica nanoparticles (MSNs).…”

“…All characterization assays were performed, as previously described by Pinto et al [5], Portilho et al [6] and de Jesus Felismino et al [7]. In summary, were done the following assays: powder X-ray diffraction, transmission electron microscopy (TEM), N 2 adsorption-desorption and superconducting quantum interference (SQUID) analysis.…”

“…The magnetic core mesoporous silica doped with trastuzumab nanoparticles were radiolabeled by the direct labelling methodology using technetium 99 metastable ( 99m Tc), as previously described by Pinto et al [5], Portilho et al [6], de Jesus Felismino et al [7] and Cerqueira-Coutinho et al [8]. Briefly, 100 mCi of previously reduced 99m Tc solution was incubated with 150 mg magnetic core mesoporous silica nanoparticles doped with trastuzumab for 10 min.…”

“…At times of 30 min, 2 h and 6 h post-injection, images were acquired using an Albira micro PET/SPECT/CT imaging system (Bruker Biospin Corporation, Woodbridge, CT). Axial, sagital and coronal, MicroSPECT/CT images were performed [6].…”